These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 32245205)

  • 1. Combined Treatment with Sodium-Glucose Cotransporter-2 Inhibitor (Canagliflozin) and Dipeptidyl Peptidase-4 Inhibitor (Teneligliptin) Alleviates NASH Progression in A Non-Diabetic Rat Model of Steatohepatitis.
    Ozutsumi T; Namisaki T; Shimozato N; Kaji K; Tsuji Y; Kaya D; Fujinaga Y; Furukawa M; Nakanishi K; Sato S; Sawada Y; Saikawa S; Kitagawa K; Takaya H; Kawaratani H; Kitade M; Moriya K; Noguchi R; Akahane T; Mitoro A; Yoshiji H
    Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32245205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular Carcinoma.
    Jojima T; Wakamatsu S; Kase M; Iijima T; Maejima Y; Shimomura K; Kogai T; Tomaru T; Usui I; Aso Y
    Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31652578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of combined treatment with canagliflozin and teneligliptin on glucose intolerance in Zucker diabetic fatty rats.
    Oguma T; Kuriyama C; Nakayama K; Matsushita Y; Yoshida K; Kiuchi S; Ikenaga Y; Nakamaru Y; Hikida K; Saito A; Arakawa K; Oka K; Ueta K; Shiotani M
    J Pharmacol Sci; 2015 Apr; 127(4):456-61. PubMed ID: 25892328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ezetimibe suppresses development of liver tumors by inhibiting angiogenesis in mice fed a high-fat diet.
    Miura K; Ohnishi H; Morimoto N; Minami S; Ishioka M; Watanabe S; Tsukui M; Takaoka Y; Nomoto H; Isoda N; Yamamoto H
    Cancer Sci; 2019 Feb; 110(2):771-783. PubMed ID: 30520543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination treatment of angiotensin II type I receptor blocker and new oral iron chelator attenuates progression of nonalcoholic steatohepatitis in rats.
    Kaji K; Yoshiji H; Kitade M; Ikenaka Y; Noguchi R; Shirai Y; Aihara Y; Namisaki T; Yoshii J; Yanase K; Tsujimoto T; Kawaratani H; Fukui H
    Am J Physiol Gastrointest Liver Physiol; 2011 Jun; 300(6):G1094-104. PubMed ID: 21372165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined treatment with dipeptidyl peptidase-4 inhibitor (sitagliptin) and angiotensin-II type 1 receptor blocker (losartan) suppresses progression in a non-diabetic rat model of steatohepatitis.
    Okura Y; Namisaki T; Moriya K; Kitade M; Takeda K; Kaji K; Noguchi R; Nishimura N; Seki K; Kawaratani H; Takaya H; Sato S; Sawada Y; Shimozato N; Furukawa M; Nakanishi K; Saikawa S; Kubo T; Asada K; Yoshiji H
    Hepatol Res; 2017 Nov; 47(12):1317-1328. PubMed ID: 28029729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beneficial effects of combined ursodeoxycholic acid and angiotensin-II type 1 receptor blocker on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis.
    Namisaki T; Noguchi R; Moriya K; Kitade M; Aihara Y; Douhara A; Nishimura N; Takeda K; Okura Y; Kawaratani H; Takaya H; Seki K; Yoshiji H
    J Gastroenterol; 2016 Feb; 51(2):162-72. PubMed ID: 26190501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake.
    Kaji K; Nishimura N; Seki K; Sato S; Saikawa S; Nakanishi K; Furukawa M; Kawaratani H; Kitade M; Moriya K; Namisaki T; Yoshiji H
    Int J Cancer; 2018 Apr; 142(8):1712-1722. PubMed ID: 29205334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acyclic retinoid and angiotensin-II receptor blocker exert a combined protective effect against diethylnitrosamine-induced hepatocarcinogenesis in diabetic OLETF rats.
    Nishimura N; Kaji K; Kitade M; Aihara Y; Sato S; Seki K; Sawada Y; Takaya H; Okura Y; Kawaratani H; Moriya K; Namisaki T; Mitoro A; Yoshiji H
    BMC Cancer; 2018 Nov; 18(1):1164. PubMed ID: 30477453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluvastatin attenuates hepatic steatosis-induced fibrogenesis in rats through inhibiting paracrine effect of hepatocyte on hepatic stellate cells.
    Chong LW; Hsu YC; Lee TF; Lin Y; Chiu YT; Yang KC; Wu JC; Huang YT
    BMC Gastroenterol; 2015 Feb; 15():22. PubMed ID: 25886887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lactoferrin Prevents Hepatic Injury and Fibrosis via the Inhibition of NF-κB Signaling in a Rat Non-Alcoholic Steatohepatitis Model.
    Aoyama Y; Naiki-Ito A; Xiaochen K; Komura M; Kato H; Nagayasu Y; Inaguma S; Tsuda H; Tomita M; Matsuo Y; Takiguchi S; Takahashi S
    Nutrients; 2021 Dec; 14(1):. PubMed ID: 35010924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation.
    Bates J; Vijayakumar A; Ghoshal S; Marchand B; Yi S; Kornyeyev D; Zagorska A; Hollenback D; Walker K; Liu K; Pendem S; Newstrom D; Brockett R; Mikaelian I; Kusam S; Ramirez R; Lopez D; Li L; Fuchs BC; Breckenridge DG
    J Hepatol; 2020 Oct; 73(4):896-905. PubMed ID: 32376414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Dipeptidyl Peptidase-4 Inhibitor Teneligliptin Attenuates Hepatic Lipogenesis via AMPK Activation in Non-Alcoholic Fatty Liver Disease Model Mice.
    Ideta T; Shirakami Y; Miyazaki T; Kochi T; Sakai H; Moriwaki H; Shimizu M
    Int J Mol Sci; 2015 Dec; 16(12):29207-18. PubMed ID: 26670228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fucoxanthin inhibits hepatic oxidative stress, inflammation, and fibrosis in diet-induced nonalcoholic steatohepatitis model mice.
    Takatani N; Kono Y; Beppu F; Okamatsu-Ogura Y; Yamano Y; Miyashita K; Hosokawa M
    Biochem Biophys Res Commun; 2020 Jul; 528(2):305-310. PubMed ID: 32475638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined effect of a farnesoid X receptor agonist and dipeptidyl peptidase-4 inhibitor on hepatic fibrosis.
    Shimozato N; Namisaki T; Kaji K; Kitade M; Okura Y; Sato S; Moriya K; Seki K; Kawaratani H; Takaya H; Sawada Y; Saikawa S; Nakanishi K; Furukawa M; Fujinaga Y; Kubo T; Asada K; Kitagawa K; Tsuji Y; Kaya D; Ozutsumi T; Akahane T; Mitoro A; Yoshiji H
    Hepatol Res; 2019 Oct; 49(10):1147-1161. PubMed ID: 31177586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polaprezinc attenuates liver fibrosis in a mouse model of non-alcoholic steatohepatitis.
    Sugino H; Kumagai N; Watanabe S; Toda K; Takeuchi O; Tsunematsu S; Morinaga S; Tsuchimoto K
    J Gastroenterol Hepatol; 2008 Dec; 23(12):1909-16. PubMed ID: 18422963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Silymarin suppresses hepatic stellate cell activation in a dietary rat model of non-alcoholic steatohepatitis: analysis of isolated hepatic stellate cells.
    Kim M; Yang SG; Kim JM; Lee JW; Kim YS; Lee JI
    Int J Mol Med; 2012 Sep; 30(3):473-9. PubMed ID: 22710359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on ongoing hepatic fibrosis.
    Namisaki T; Kaji K; Shimozato N; Kaya D; Ozutsumi T; Tsuji Y; Fujinaga Y; Kitagawa K; Furukawa M; Sato S; Sawada Y; Nishimura N; Takaya H; Okura Y; Seki K; Kawaratani H; Moriya K; Noguchi R; Asada K; Akahane T; Mitoro A; Yoshiji H
    Indian J Gastroenterol; 2022 Apr; 41(2):169-180. PubMed ID: 35279807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effective Combination Therapy of Angiotensin-II Receptor Blocker and Rifaximin for Hepatic Fibrosis in Rat Model of Nonalcoholic Steatohepatitis.
    Fujinaga Y; Kawaratani H; Kaya D; Tsuji Y; Ozutsumi T; Furukawa M; Kitagawa K; Sato S; Nishimura N; Sawada Y; Takaya H; Kaji K; Shimozato N; Moriya K; Namisaki T; Akahane T; Mitoro A; Yoshiji H
    Int J Mol Sci; 2020 Aug; 21(15):. PubMed ID: 32759852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growth differentiation factor 15 ameliorates nonalcoholic steatohepatitis and related metabolic disorders in mice.
    Kim KH; Kim SH; Han DH; Jo YS; Lee YH; Lee MS
    Sci Rep; 2018 May; 8(1):6789. PubMed ID: 29717162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.